vasodilators therapy

Buflomedil - Epoprostenol      

pathologytreatmentpatient Demonstrated benefit and harm k      
heart failureepoprostenolnot classified

versus placebo or no treatment

No demonstrated result for efficacy

epoprostenol inferior to standard care in terms of All cause death in FIRST, 1997

1 trialmeta-analysis
heart failurehydralazinenot classified

versus placebo or no treatment

No demonstrated result for efficacy

4 trialsmeta-analysis
heart failurehydralazine-ISDNnot classified

versus placebo or no treatment

No demonstrated result for efficacy

1 trialmeta-analysis
heart failureisosorbide dinitratenot classified

versus placebo or no treatment

No demonstrated result for efficacy

2 trialsmeta-analysis
heart failurenesiritidenot classified

versus placebo or control

No demonstrated result for efficacy

nesiritide inferior to placebo in terms of amelioration of Dyspnea at 24 h in ASCEND-HF, 2011

7 trialsmeta-analysis
heart failurenesiritidenot classified

versus active treatment

No demonstrated result for efficacy

3 trialsmeta-analysis
peripheral vascular diseasesbuflomedilnot classified

versus placebo or control

No demonstrated result for efficacy

2 trialsmeta-analysis
peripheral vascular diseasescilostazolnot classified

versus placebo or control

No demonstrated result for efficacy

7 trialsmeta-analysis
peripheral vascular diseasesginko bilobanot classified

versus placebo or control

No demonstrated result for efficacy

2 trialsmeta-analysis
peripheral vascular diseasesnaftidrofurylnot classified

versus placebo or control

No demonstrated result for efficacy

7 trialsmeta-analysis
peripheral vascular diseasesnaftidrofurylnot classified

versus prostaglandine

No demonstrated result for efficacy

1 trialmeta-analysis
peripheral vascular diseasespentoxifyllinenot classified

versus placebo or control

No demonstrated result for efficacy

5 trialsmeta-analysis